Euroopa Liit - eesti - EMA (European Medicines Agency)

novartis europharm limited  - gozetotide - radionukliidi pildistamine - diagnostilised radiofarmatseutilised ühendid - see ravim on mõeldud ainult diagnostiliseks kasutamiseks. locametz, after radiolabelling with gallium 68, is indicated for the detection of prostate specific membrane antigen (psma) positive lesions with positron emission tomography (pet) in adults with prostate cancer (pca) in the following clinical settings:primary staging of patients with high risk pca prior to primary curative therapy,suspected pca recurrence in patients with increasing levels of serum prostate specific antigen (psa) after primary curative therapy,identification of patients with psma positive progressive metastatic castration resistant prostate cancer (mcrpc) for whom psma targeted therapy is indicated (see section 4.

Euroopa Liit - eesti - EMA (European Medicines Agency)

novartis europharm limited  - lutetium (177lu) vipivotide tetraxetan - prostatic kasvajad, kastreerimine-vastupidavad - terapeutilised radiofarmatseutilised ühendid - pluvicto in combination with androgen deprivation therapy (adt) with or without androgen receptor (ar) pathway inhibition is indicated for the treatment of adult patients with progressive prostate-specific membrane antigen (psma)-positive metastatic castration-resistant prostate cancer (mcrpc) who have been treated with ar pathway inhibition and taxane based chemotherapy.

Euroopa Liit - eesti - EMA (European Medicines Agency)

novartis europharm limited - tislelizumab - esophageal squamous cell carcinoma - antineoplastilised ained - oesophageal squamous cell carcinoma (oscc) tevimbra as monotherapy is indicated for the treatment of adult patients with unresectable, locally advanced or metastatic oesophageal squamous cell carcinoma after prior platinum-based chemotherapy.

Euroopa Liit - eesti - EMA (European Medicines Agency)

novartis europharm ltd - serelaxin - südamepuudulikkus - muud vasodilators, mida kasutatakse südame haiguste - ravi ägeda südamepuudulikkuse.

Euroopa Liit - eesti - EMA (European Medicines Agency)

novartis europharm limited - tegaserod - Ärritunud soole sündroom - funktsionaalsete seedetrakti häirete ravimid - zelnorm on näidustatud korduvate sümptomitega lühiajaline ravi naistel Ärritatud soole sündroom (ibs), kelle domineeriv soole harjumus on kõhukinnisus, mis on seotud kõhuvalu/ebamugavustunne või kõhupuhitus (vt lõik 4.

Eesti - eesti - Ravimiamet

neuraxpharm pharmaceuticals s.l. - midasolaam - suuõõnelahus - 10mg 2ml 2ml 4tk

Eesti - eesti - Ravimiamet

neuraxpharm pharmaceuticals s.l. - midasolaam - suuõõnelahus - 7,5mg 1.5ml 1.5ml 4tk

Eesti - eesti - Ravimiamet

mcneil healthcare (ireland) limited - ksülometasoliin+dekspantenool - ninasprei, lahus - 0,5mg+50mg 1ml 10ml 1tk

Eesti - eesti - Ravimiamet

mcneil healthcare (ireland) limited - ksülometasoliin - ninasprei, lahus - 0,5mg 1ml 10ml 1tk

Eesti - eesti - Ravimiamet

mcneil healthcare (ireland) limited - ksülometasoliin+dekspantenool - ninasprei, lahus - 1mg+50mg 1ml 10ml 1tk